Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

BACKGROUND: Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium–glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared the risk of several CV outcomes between new users of SGLT2i...

Descripción completa

Detalles Bibliográficos
Autores principales: Real, Jordi, Vlacho, Bogdan, Ortega, Emilio, Vallés, Joan Antoni, Mata-Cases, Manel, Castelblanco, Esmeralda, Wittbrodt, Eric T., Fenici, Peter, Kosiborod, Mikhail, Mauricio, Dídac, Franch-Nadal, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272340/
https://www.ncbi.nlm.nih.gov/pubmed/34243779
http://dx.doi.org/10.1186/s12933-021-01323-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272340/
https://www.ncbi.nlm.nih.gov/pubmed/34243779
http://dx.doi.org/10.1186/s12933-021-01323-5

Ejemplares similares